RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $131
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has maintained its 'Outperform' rating on Axsome Therapeutics and slightly raised the price target from $130 to $131.
October 04, 2024 | 4:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reaffirmed its positive outlook on Axsome Therapeutics by maintaining an 'Outperform' rating and slightly increasing the price target to $131.
The reaffirmation of the 'Outperform' rating and the slight increase in the price target by RBC Capital suggests continued confidence in Axsome Therapeutics' performance. This is likely to have a positive short-term impact on the stock price as it signals to investors that the company is expected to perform well.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100